CoChat

Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma

Open access

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Epcoritamab is a subcutaneous CD3×CD20 bispecific antibody approved as monotherapy for relapsed/refractory (R/R) follicular lymphoma (FL). We evaluated fixed-duration epcoritamab with rituximab plus lenalidomide (R2) in R/R FL in arm 2 of EPCORE NHL-2 (phase 1b/2). Patients received epcoritamab (2 step-up doses, then 48-mg full doses) for up to 2 years, and R2 for up to 12 cycles (28 days per cycle). The primary end point was overall response rate (ORR) per investigator assessment (Lugano criteria). As of 21 September 2024, 108 patients received ≥1 epcoritamab dose in expansion (median follow-up, 28.2 months). Median age was 65 years; 57% had 1 previous line of therapy. ORR and complete response (CR) rate were 96% and 88%, respectively; CR rates in patients with high-risk features were 90% (primary refractory), 82% (refractory to anti-CD20 and an alkylating agent), and 83% (disease progression within 24 months of first-line therapy). Two-year estimates for remaining in CR, progression-free survival, overall survival, and not starting next antilymphoma therapy were 82%, 76%, 90%, and 84%, respectively. Minimal residual disease negativity was observed in 86% of evaluable patients (clonoSEQ assay). Common treatment-emergent adverse events (TEAEs) included neutropenia (65%), COVID-19 (59%), and cytokine release syndrome (CRS; 51%). Grade ≥3 TEAEs occurred in 87% of patients; 5 had grade 5 TEAEs (all COVID-19). CRS events were mostly low grade (grade 1, 38%; grade 2, 11%; grade 3, 2%), all resolved, and none led to epcoritamab discontinuation. Fixed-duration epcoritamab plus R2 demonstrated deep, durable responses with manageable safety and favorable outcomes in R/R FL, irrespective of risk features. This trial was registered at www.ClinicalTrials.gov as #NCT04663347.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2025029909

Cites

Statistics

Figures

Graphical abstract Visual Abstract
Graphical abstract Visual AbstractCC BY-NC-ND · PubMed Central
Figure 1. Waterfall plot. Best percentage change from baseline in the sum of products of perpendicular diameters of target lesions for patients with R/R FL by best overall response per Lugano criteria by investigator assessment is shown. Patients evaluable for change from baseline in tumor size (n = 107) are shown; 1 patient was excluded due to the absence of baseline tumor measurements. Dashed line indicates a 50% reduction in tumor size compared with baseline. NE, not evaluable.
Figure 1. Waterfall plot. Best percentage change from baseline in the sum of products of perpendicular diameters of target lesions for patients with R/R FL by best overall response per Lugano criteria by investigator assessment is shown. Patients evaluable for change from baseline in tumor size (n = 107) are shown; 1 patient was excluded due to the absence of baseline tumor measurements. Dashed line indicates a 50% reduction in tumor size compared with baseline. NE, not evaluable.CC BY-NC-ND · PubMed Central
Figure 2. Response per Lugano criteria by investigator assessment in prespecified groups. (A) ORRs and (B) CR rates. aBulky disease per investigator. bRefractory: disease progression or stable disease as best response to therapy or disease progression within 6 months after completion of therapy. cPrimary refractory: refractory to 1L antilymphoma therapy. dDouble refractory: refractory to both anti-CD20 and an alkylating agent. 3L+, received epcoritamab plus R2 in the third line or later; FLIPI, Follicular Lymphoma International Prognostic Index; POD24 2L, progression of disease within 24 months after 1L therapy and received epcoritamab plus R2 in the 2L.
Figure 2. Response per Lugano criteria by investigator assessment in prespecified groups. (A) ORRs and (B) CR rates. aBulky disease per investigator. bRefractory: disease progression or stable disease as best response to therapy or disease progression within 6 months after completion of therapy. cPrimary refractory: refractory to 1L antilymphoma therapy. dDouble refractory: refractory to both anti-CD20 and an alkylating agent. 3L+, received epcoritamab plus R2 in the third line or later; FLIPI, Follicular Lymphoma International Prognostic Index; POD24 2L, progression of disease within 24 months after 1L therapy and received epcoritamab plus R2 in the 2L.CC BY-NC-ND · PubMed Central
Figure 3. Patient outcomes. Kaplan-Meier plots of DOR in patients with CR or PR per Lugano criteria by investigator assessment (A); DOCR in patients with CR per Lugano criteria by investigator assessment (B); PFS by investigator assessment (C); and OS overall and in patients with POD24, primary refractory disease (disease refractory to 1L antilymphoma therapy), and double-refractory disease (disease refractory to both anti-CD20 and an alkylating agent) (D). Kaplan-Meier estimates are shown. NR, not reached.
Figure 3. Patient outcomes. Kaplan-Meier plots of DOR in patients with CR or PR per Lugano criteria by investigator assessment (A); DOCR in patients with CR per Lugano criteria by investigator assessment (B); PFS by investigator assessment (C); and OS overall and in patients with POD24, primary refractory disease (disease refractory to 1L antilymphoma therapy), and double-refractory disease (disease refractory to both anti-CD20 and an alkylating agent) (D). Kaplan-Meier estimates are shown. NR, not reached.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 33 · Cited by 15

Research works printed but not linked: 2

  1. Serna, 2025, Rituximab maintenance after bendamustine-based treatment for follicular lymphoma and mantle cell lymphoma may exert a negative influence on SARS-CoV-2 infection outcomes, Haematologica, 110, 173
  2. Sehn, 2024, Tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: results from a phase 3 study (inMIND) [abstract], Blood, 144

Metadata

Authors
Falchi, L., Sureda, A., Leppä, S., Vermaat, J. S. P., Nijland, M., Christensen, J. H., de Vos, S., Holte, H., Merryman, R. W., Lugtenburg, P. J., Abrisqueta, P., Linton, K. M., Sunkersett, G., Hoehn, D., Rana, A., Abbas, A., Marek, J., Hao, Y., Steele, A. J., Morehouse, C., Hutchings, M., & Belada, D.
Affiliations
  • Memorial Sloan Kettering Cancer Center (US)
  • Institut d'Investigació Biomédica de Bellvitge (ES)
  • University of Helsinki (FI)
  • Leiden University Medical Center (NL)
  • University Medical Center Groningen (NL)
  • Odense University Hospital (DK)
  • 7Department of Medicine, Hematology/Oncology, Ronald Reagan University of California Los Angeles Medical Center, Los Angeles, CA
  • Oslo University Hospital (NO)
  • Dana-Farber Cancer Institute (US)
  • Erasmus MC (NL)
  • Vall d'Hebron Hospital Universitari (ES)
  • University of Manchester (GB)
  • AbbVie (United States) (US)
  • Genmab (United States) (US)
  • University of Copenhagen (DK)
  • Charles University (CZ)
Corresponding author
  • Falchi, Lorenzo
  • Belada, David
Venue
Blood
Published
2025-11-27
Volume
146
Issue
22
Pages
2629-2640
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W4414057143
Cited by
15
References
33
Citations by year
2026: 11 · 2025: 4
FWCI
9.91
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Blood (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (acceptedVersion, cc-by-nc-nd)
  • Leiden Repository (Leiden University) (submittedVersion, cc-by-nc-nd)
  • Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, cc-by-nc-nd)
  • Työväentutkimus Vuosikirja (submittedVersion)
  • Research Explorer (The University of Manchester) (submittedVersion, cc-by-nc-nd)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, cc-by-nc-nd)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc-nd)
Funders
  • Amgen
  • AstraZeneca
  • Sanofi
  • Gilead Sciences
  • Regeneron Pharmaceuticals
  • BeiGene
  • Incyte
  • Seagen
  • National Institute for Health and Care Research (NIHR 203308, P30 CA008748)
  • Servier
  • Swedish Orphan Biovitrum
  • MorphoSys
  • Ipsen
  • National Institutes of Health (CA008748)
  • Genentech
  • Manchester Biomedical Research Centre (NIHR 203308)
  • National Cancer Institute (CA008748, P30CA008748)
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
  • Health Sciences › Medicine › Dermatology › Cutaneous lymphoproliferative disorders research
Keywords
epcoritamab, relapsed/refractory follicular lymphoma, rituximab, lenalidomide, overall response rate, complete response, minimal residual disease, cytokine release syndrome, COVID-19 pandemic, neutropenia, progression-free survival, high-risk features
MeSH terms
Rituximab, Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Lymphoma, Follicular, Male, Middle Aged, Neoplasm Recurrence, Local, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma. https://app.cochat.ai/papers/10.1182/blood.2025029909
The paper
Falchi, L., Sureda, A., Leppä, S., Vermaat, J. S. P., Nijland, M., Christensen, J. H., de Vos, S., Holte, H., Merryman, R. W., Lugtenburg, P. J., Abrisqueta, P., Linton, K. M., Sunkersett, G., Hoehn, D., Rana, A., Abbas, A., Marek, J., Hao, Y., Steele, A. J., . . . Belada, D. (2025). Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma. Blood. https://doi.org/10.1182/blood.2025029909

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.